Excellus BlueCross BlueShield logo

Excellus BlueCross BlueShield Says It Won’t Cover Aduhelm

August 16, 2021

New York-based Excellus BlueCross BlueShield said it will not cover Biogen’s controversial Alzheimer’s disease drug Aduhelm (aducanumab), citing concerns that the treatment is ineffective.

Excellus has joined at least six other BlueCross and BlueShield affiliates that have refused to cover the newly approved drug which is estimated to cost $56,000 a year.

Other insurers, including UnitedHealth, say they are waiting for a review of coverage by the Centers for Medicare and Medicaid Services before reaching their decision.

View today's stories